Millendo Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Julia Owens
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 110 Miller Ave Ste 100 Ann Arbor MI United States of America 48104
- IPO Date
- Oct 4, 2012
- CIK
- 0001544227
- Website
- millendo.com
- Similar Companies
- Business
- Millendo Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel treatments for endocrine diseases with significant unmet medical needs. The company's core products include livoletide, an unacylated ghrelin analogue for treating Prader-Willi syndrome (PWS), nevanimibe, a selective small molecule inhibitor of acyl-CoA cholesterol acyltransferase 1 (ACAT1) for classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome, and MLE4901, a neurokinin 3 receptor (NK3R) antagonist for polycystic ovary syndrome (PCOS). These products are advanced in clinical development phases and have received orphan drug designations from regulatory authorities. Millendo operates both in the United States and Europe, maintaining research and development facilities following its acquisition of Alizé Pharma SAS, which expanded its presence and expertise in the endocrinology therapeutic area. Founded in 2012 and headquartered in Ann Arbor, Michigan, Millendo has built a pipeline focused on orphan endocrine diseases, addressing conditions lacking adequate treatment options. The acquisition of Alizé Pharma SAS in 2017 brought two first-in-class, late-stage clinical assets, livoletide and nevanimibe, into Millendo’s portfolio, reinforcing its commitment to endocrinology. The company is actively advancing pivotal clinical trials for its lead programs, including livoletide for PWS and nevanimibe for CAH. In a significant recent development, Millendo Therapeutics merged with Tempest Therapeutics, Inc. in a reverse merger transaction completed in 2024, valued at approximately $180 million, after which the combined entity adopted the Tempest Therapeutics name. This strategic transaction marked a major operational change streamlining the company's focus and resource allocation toward innovative therapeutic areas. Millendo has also closed notable funding rounds, including a $62 million Series B capital raise used to license the PCOS drug candidate MLE4901 from AstraZeneca, acquiring global rights for development and commercialization, thereby expanding its product pipeline. Millendo’s business segments include specialty pharmaceuticals targeting endocrine disorders and orphan diseases, with a strategic foothold in the U.S. and European markets. The company serves healthcare providers, patients affected by rare endocrine conditions, and the broader pharmaceutical market seeking novel therapies for hormone-related diseases. Its expertise spans drug development, clinical research, and regulatory processes in endocrinology. The merger and expanded pipeline underscore Millendo’s evolving strategy to become a leading endocrinology-focused biotechnology company by delivering transformative treatments for rare endocrine diseases.
Tempest and Millendo Announce Stockholder Approval of Merger
MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND
MLND Stock Price Falls Over 10% Pre-Market: Why It Happened
Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
Tempest and Millendo Announce Proposed Merger Agreement
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics (NASDAQ:MLND) Cut to “Hold” at Zacks Investment Research
Zacks Investment Research Upgrades Millendo Therapeutics (NASDAQ:MLND) to Buy
Millendo Therapeutics Inc (NASDAQ:MLND) Sees Significant Increase in Short Interest
Millendo Therapeutics (NASDAQ:MLND) Trading Down 3.8%
Millendo Therapeutics Provides Corporate and Pipeline Update
Millendo Therapeutics (NASDAQ:MLND) Shares Gap Down to $2.71
Millendo Therapeutics Reports First Quarter 2020 Operating and Financial Results
Leonardo books first-quarter loss, braces for higher virus impact in second quarter
GBP/CHF Continuation
USD/CAD Continuation
GBP/USD Continuation
What Are The Best Penny Stocks To Watch This Week? 3 For Your List